- Home
- GRFS vs BHVN Comparison
GRFS vs BHVN Comparison
Compare GRFS & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRFS
- BHVN
- Stock Information
- Founded
- GRFS 1940
- BHVN 2013
- Country
- GRFS Spain
- BHVN United States
- Employees
- GRFS N/A
- BHVN N/A
- Industry
- GRFS Biotechnology: Pharmaceutical Preparations
- BHVN Biotechnology: Pharmaceutical Preparations
- Sector
- GRFS Health Care
- BHVN Health Care
- Exchange
- GRFS Nasdaq
- BHVN Nasdaq
- Market Cap
- GRFS 6.0B
- BHVN 5.4B
- IPO Year
- GRFS 2006
- BHVN 2017
- Fundamental
- Price
- GRFS $9.45
- BHVN $44.39
- Analyst Decision
- GRFS Sell
- BHVN Strong Buy
- Analyst Count
- GRFS 2
- BHVN 13
- Target Price
- GRFS $10.50
- BHVN $63.42
- AVG Volume (30 Days)
- GRFS 1.0M
- BHVN 725.9K
- Earning Date
- GRFS 01-01-0001
- BHVN 11-12-2024
- Dividend Yield
- GRFS N/A
- BHVN N/A
- EPS Growth
- GRFS N/A
- BHVN N/A
- EPS
- GRFS 0.27
- BHVN N/A
- Revenue
- GRFS $7,814,096,584.00
- BHVN N/A
- Revenue This Year
- GRFS $8.86
- BHVN N/A
- Revenue Next Year
- GRFS $7.00
- BHVN $179.00
- P/E Ratio
- GRFS $41.33
- BHVN N/A
- Revenue Growth
- GRFS 7.21
- BHVN N/A
- 52 Week Low
- GRFS $5.30
- BHVN $26.80
- 52 Week High
- GRFS $12.15
- BHVN $62.21
- Technical
- Relative Strength Index (RSI)
- GRFS 62.73
- BHVN 33.48
- Support Level
- GRFS $8.69
- BHVN $51.80
- Resistance Level
- GRFS $9.75
- BHVN $54.53
- Average True Range (ATR)
- GRFS 0.37
- BHVN 2.42
- MACD
- GRFS 0.06
- BHVN -0.92
- Stochastic Oscillator
- GRFS 80.27
- BHVN 9.80
About GRFS Grifols S.A.
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.